GLP-1 weight-loss drugs linked to increased hair loss risk, studies confirm

New research confirms a link between GLP-1 receptor agonists — including semaglutide and tirzepatide, used to treat type 2 diabetes and obesity — and an elevated risk of hair loss. The risk is described as low but real, and researchers say awareness of this side effect is important for informed treatment decisions.